IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Subscribe To Our Newsletter & Stay Updated
